| John Lemen Ii, DPT | |
|
1030 Forrest Ave, Dover, DE 19904-3314 | |
| (302) 268-8880 | |
| Not Available |
| Full Name | John Lemen Ii |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 19 Years |
| Location | 1030 Forrest Ave, Dover, Delaware |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760424568 | NPI | - | NPPES |
| 246555 | Other | MAMSI | |
| 5070-0060 | Other | CARE FIRST | |
| 2851044000 | Other | AMERIHEALTH IBC | |
| 1598815128 | Other | CHAMPUS TRICARE | |
| 88760501 | Other | CARE FIRST | |
| 1000037866 | Medicaid | DE | |
| 11741834 | Other | CAQH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | J10001982 (Delaware) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Callaway Franceschini Llc | 4880024496 | 21 |
News Archive
Myeloid-derived suppressor cells (MDSCs) are a population of immune cells that have been implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotherapy.
According to a study published today by a Finnish-English research group, a switch from 5-yearly screen intervals to individualized intervals could annually prevent 8% of myocardial infarcts and strokes without increasing health care costs.
The U.S. Food and Drug Administration today cautioned users of personal emergency response buttons worn around the neck of a potential choking hazard associated with this product.
Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.
› Verified 9 days ago
| Provider Name | Callaway Franceschini Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1790319895 PECOS PAC ID: 4880024496 Enrollment ID: O20200423000073 |
News Archive
Myeloid-derived suppressor cells (MDSCs) are a population of immune cells that have been implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotherapy.
According to a study published today by a Finnish-English research group, a switch from 5-yearly screen intervals to individualized intervals could annually prevent 8% of myocardial infarcts and strokes without increasing health care costs.
The U.S. Food and Drug Administration today cautioned users of personal emergency response buttons worn around the neck of a potential choking hazard associated with this product.
Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Lemen Ii, DPT 255 Avonbridge Dr, Townsend, DE 19734-2868 Ph: (302) 494-5738 | John Lemen Ii, DPT 1030 Forrest Ave, Dover, DE 19904-3314 Ph: (302) 268-8880 |
News Archive
Myeloid-derived suppressor cells (MDSCs) are a population of immune cells that have been implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotherapy.
According to a study published today by a Finnish-English research group, a switch from 5-yearly screen intervals to individualized intervals could annually prevent 8% of myocardial infarcts and strokes without increasing health care costs.
The U.S. Food and Drug Administration today cautioned users of personal emergency response buttons worn around the neck of a potential choking hazard associated with this product.
Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.
› Verified 9 days ago
Adrianne Greene, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1288 S Governors Ave, Dover, DE 19904 Phone: 302-677-0100 Fax: 302-677-0267 | |
Ms. Amy Kathryn Tullis, PT, MPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 97 Commerce Way, Suite 101, Dover, DE 19904 Phone: 302-734-8000 | |
Jihwan Jeong, Physical Therapist Medicare: Medicare Enrolled Practice Location: 1288 S Governors Ave, Dover, DE 19904 Phone: 302-677-0100 | |
Matthew Vassalotti, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1288 S Governors Ave, Dover, DE 19904 Phone: 302-677-0100 Fax: 302-677-0267 | |
Kathy Tompkins, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 945 Forest St, Dover, DE 19904 Phone: 302-672-1500 | |
Christine Marie Reynolds, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1203 Walker Rd, Dover, DE 19904 Phone: 302-735-8800 | |
Katherine Marie Monahan, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1288 S Governors Ave, Dover, DE 19904 Phone: 302-677-0100 |